Physicians' Academy for Cardiovascular Education

Novel insights and innovations in targeting the neurohumoral system

Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer

Video navigation menu

  • Current medication to improve morbidity/mortality in HFrEF 0:00
  • PARADIGM-HF trial: LCZ696 compared with enalapril with respect to morbidity/mortality 0:37
  • ATMOSPHERE trial - aliskiren compared with enalapril 1:42
  • Potassium-binding drugs to lower hyperkalemia 2:19
  • Conclusion - cornerstone drug therapy in HFrEF and new treatment modalities 3:11